Skinvisible

Skinvisible EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Skinvisible (SKVI) as of Nov 4, 2026 is 12.80 %. In the previous year, Year-over-Year EBITDA Growth was -20.70 % — a change of -161.85% (higher).

EBITDA Growth YoY

12.80 %

YoY

-161.85%

Last updated:

Year-over-Year EBITDA Growth of Skinvisible is 2025 12.80 % . Year-over-Year EBITDA Growth of Skinvisible was 2024 -20.70 % . It decreases by -161.85% higher compared to the previous year.

The Skinvisible EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-80.44 USD
Jan 1, 2019
10.51 USD
Jan 1, 2020
55.68 USD
Jan 1, 2021
192.92 USD
Jan 1, 2022
-206.68 USD
Jan 1, 2023
-114.61 USD
Jan 1, 2024
-20.70 USD
Jan 1, 2025
12.80 USD
The Skinvisible EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
12.80 %-161.85%
-20.70 %-81.94%
-114.61 %-44.54%
-206.68 %-207.13%
192.92 %+246.47%
55.68 %+429.68%
10.51 %-113.07%
-80.44 %-232.98%
60.49 %+159.30%
23.33 %+154.28%
9.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Skinvisible stock

Year-over-Year EBITDA Growth of Skinvisible is 12.80 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Skinvisible since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Skinvisible historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Skinvisible

All Key Metrics — Skinvisible